RE:RE:RE:RE:Conditions are right for biopharma M&A to break outJune 06, 2023 - RBC Capital - Ahmed Attia: The reality is that the deal chessboard is active. And the larger players recognize that their competitors are going to zone in on the same assets.
I think the pillars that are driving some of the M&A include the need to accelerate top-line growth. Growth is still a key driver for large-cap players. And fundamentally, the market has been rewarding businesses that are excelling in that regard.
There has also been a heightened focus by larger players in the space to really build scale. M&As between strong businesses that give very differentiated capabilities are a dynamic that continues to drive a lot of focus in pharma services.
We are bullish that the pharma services space will continue being highly active. We’ve seen a lot of investments made by financial sponsors over the last few years.